Neurosearch said the charges were related to an announcement in February 2010 in which the management of the company reported top-line results from a Phase III study with its Huntington's disease drug candidate Huntexil and then two months later reassessed and corrected the data in a new announcement.
"On the present basis, Neurosearch is denying the charges and is collaborating fully with the authorities in order to resolve the matter," the company said in a statement.
(Reporting by John Acher)
Copyright 2013 mojeNovosti.com
web developer: BTGcms